

The following sensitivity analyses were undertaken to explore the impact of six cycles of chemotherapy, different combinations of chemotherapy and PLAT, trials with <24 month follow-up and the one study with PEM + CARB which is not licensed in the UK.

TABLE 96 Summary results for the direct meta-analysis and Mixed-treatment comparison (HR, 95% CI) for 1-year survival for trials comparing chemotherapy vs chemotherapy in population 2: population with non-squamous disease

Reference treatment vs comparator	Direct meta-analysis 1 (n = 19), HR (95% CI)	Mixed-treatment comparison 1 (n = 19), HR (95% CI)	Mixed-treatment comparison A (n = 17), HR (95% CI)	Mixed-treatment comparison B (n = 19), HR (95% CI)	Mixed-treatment comparison C (n = 18), HR (95% CI)	Mixed-treatment comparison D (n = 18), HR (95% CI)	Mixed-treatment comparison E (n = 18), HR (95% CI)	Mixed-treatment comparison F, (n = 18), HR (95% CI)
GEM + PLAT vs VNB + PLAT ^{43,45,49,50,54,55,57}	0.90 (0.81 to 1.02)	0.93 (0.83 to 1.05)	0.94 (0.83 to 1.06)	0.94 (0.83 to 1.06)	0.93 (0.83 to 1.05)	0.94 (0.85 to 1.06)	0.94 (0.83 to 1.06)	0.94 (0.83 to 1.06)
GEM + PLAT vs PAX + PLAT ^{43,46,47,56,57,60}	1.00 (0.90 to 1.10)	0.96 (0.86 to 1.08)	0.96 (0.85 to 1.08)	0.96 (0.85 to 1.08)	0.94 (0.84 to 1.06)	0.96 (0.86 to 1.07)	0.96 (0.85 to 1.08)	0.96 (0.85 to 1.08)
GEM + PLAT vs DOC + PLAT ⁴⁷	0.86 (0.69 to 1.09) ^a	0.97 (0.83 to 1.14)	0.97 (0.80 to 1.17)	0.97 (0.79 to 1.17)	0.98 (0.83 to 1.15)	0.92 (0.79 to 1.08)	0.98 (0.81 to 1.16)	0.97 (0.82 to 1.15)
GEM + PLAT vs PEM + PLAT ^{61,62}	1.20 (1.05 to 1.36)	1.18 (0.97 to 1.41)	1.18 (0.95 to 1.43)	1.23 (0.95 to 1.58)	1.18 (0.96 to 1.42)	1.19 (0.99 to 1.40)	1.23 (0.97 to 1.56)	1.23 (0.97 to 1.55)
VNB + PLAT vs PAX + PLAT ^{43,48,51,57}	0.89 (0.78 to 1.01)	1.03 (0.90 to 1.18)	1.02 (0.89 to 1.18)	1.02 (0.88 to 1.18)	1.01 (0.88 to 1.16)	1.02 (0.89 to 1.16)	1.03 (0.89 to 1.18)	1.02 (0.89 to 1.17)
VNB + PLAT vs DOC + PLAT ^{44,52,53,59}	1.09 (0.97 to 1.23)	1.05 (0.91 to 1.19)	1.04 (0.86 to 1.23)	1.04 (0.85 to 1.23)	1.05 (0.91 to 1.20)	0.97 (0.85 to 1.11)	1.05 (0.88 to 1.22)	1.04 (0.89 to 1.20)
VNB + PLAT vs PEM + PLAT	XX	1.27 (1.01 to 1.56)	1.26 (0.98 to 1.58)	1.31 (0.98 to 1.73)	1.27 (1.00 to 1.57)	1.26 (1.01 to 1.53)	1.31 (1.00 to 1.71)	1.31 (1.01 to 1.70)
PAX + PLAT vs DOC + PLAT ⁴⁷	1.01 (0.79 to 1.29) ^a	1.02 (0.85 to 1.21)	1.01 (0.82 to 1.24)	1.02 (0.81 to 1.24)	1.04 (0.86 to 1.24)	0.96 (0.80 to 1.14)	1.02 (0.83 to 1.23)	1.01 (0.84 to 1.22)
PAX + PLAT vs PEM + PLAT	XX	1.23 (0.98 to 1.52)	1.23 (0.96 to 1.54)	1.28 (0.96 to 1.70)	1.25 (0.99 to 1.56)	1.24 (0.99 to 1.51)	1.28 (0.98 to 1.68)	1.28 (0.98 to 1.66)
DOC + PLAT vs PEM + PLAT	XX	1.21 (0.94 to 1.54)	1.21 (0.92 to 1.60)	1.26 (0.92 to 1.75)	1.21 (0.94 to 1.55)	1.29 (1.01 to 1.62)	1.26 (0.94 to 1.71)	1.26 (0.95 to 1.70)

XX, no direct meta-analysis or Mixed-treatment comparison undertaken.

^a Direct evidence available. Direct meta-analysis A and mixed-treatment comparison B: sensitivity analysis using data from PAX + CIS instead of PAX + CARB from the Schiller *et al.* trial.⁴⁷ Direct meta-analysis C and mixed-treatment comparison C: sensitivity analysis using data from DOC + CARB instead of DOC + CIS from the Fossella *et al.* trial.⁴⁴ Direct meta-analysis D and mixed-treatment comparison D: sensitivity analysis excluding Tan *et al.*⁵⁹ (used six cycles of chemotherapy). Direct meta-analysis E and mixed-treatment comparison E: sensitivity analysis excluding Chen *et al.*⁵² (<24 months follow-up time). Direct meta-analysis F and mixed-treatment comparison F: sensitivity analysis excluding Gronberg *et al.*⁶² (contains PEM + CARB which is not licensed in the UK).

A HR > 1 favours the reference treatment and a HR < 1 favours the comparator treatment. Bold text indicates statistically significant result.